Name
Dermatology Group Medical Visits for Hidradenitis Suppurativa in Primary Care with Behavioral Health Consultants
Description

Hidradenitis Suppurativa (HS) is a severe inflammatory condition characterized by painful lesions, affecting up to 4% of the population and often going undiagnosed for up to a decade, with women of color being disproportionately impacted. This stigmatizing disease increases the risk of mental health disorders and substance abuse, and accessing interdisciplinary care is particularly challenging in rural and marginalized communities. A novel approach integrating dermatology and behavioral health through group medical visits at a rural Federally Qualified Health Center (FQHC) shows promise in enhancing patient experience, improving outcomes, and reducing healthcare costs. This presentation will demonstrate the progression from pilot data presented in 2024 at the CFHA conference to a more structured monthly group model, highlighting the potential for further quality improvement initiatives and better support for HS patients in primary care settings.

Courtney Valentine Paulina Serrato Padilla
Content Level
All Audience
Tags
Behavioral Medicine Topics such as insomnia or medication adherence, Team-based care, Underserved populations such as LGBTQ+
Session Type
Concurrent
SIG or Committee
Medicine
Objective 1
Gaining awareness and understanding of Hidradenitis Suppurativa (HS)
Objective 2
Identify components of Group Medical Visit to address HS
Objective 3
Investigate ways to increase psychoeducation and supports for HS patients in primary care
Content Reference 1

Caccavale, S., Tancredi, V., Boccellino, M. P., Babino, G., Fulgione, E., & Argenziano, G. (2023). Hidradenitis suppurativa burdens on mental health: A literature review of associated psychiatric disorders and their pathogenesis. Life, 13(1), 189. https://doi.org/10.3390/life13010189

Content Reference 2

Cunningham SD, Sutherland RA, Yee CW, Thomas JL, Monin JK, Ickovics JR, Lewis JB. Group Medical Care: A Systematic Review of Health Service Performance. Int J Environ Res Public Health. 2021 Dec 2;18(23):12726. doi: 10.3390/ijerph182312726. PMID: 34886452; PMCID: PMC8657170.

Content Reference 3

Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. May 2020;82(5):1045-1058.

Content Reference 4

Shih T, De DR, Rick J, Shi VY, Hsiao JL. Low Rates of Psychosocial Screening and Lifestyle Counseling in Hidradenitis Suppurativa Patients in the USA. Skin Appendage Disord. 2023 Mar;9(2):94-98. doi: 10.1159/000528253. Epub 2023 Jan 5. PMID: 36937161; PMCID: PMC10015644.

Content Reference 5

Phan K, Huo YR, Smith SD. Hidradenitis suppurativa and psychiatric comorbidities, suicides and substance abuse: systematic review and meta-analysis. Ann Transl Med. 2020 Jul;8(13):821. doi: 10.21037/atm-20-1028. PMID: 32793666; PMCID: PMC7396254.